|
業務類別
|
Biotechnology |
|
業務概覽
|
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment. |
| 公司地址
| 12526 High Bluff Drive, Suite 345, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 345-6265 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.imagenebio.com |
| 員工數量
| 15 |
| Dr. Benjamin Porter-Brown, M.D. |
Chief Medical Officer |
-- |
30/04/2026 |
| Mr. Bob Lally |
Principal Accounting Officer and Senior Vice President, Finance and Operations |
-- |
17/03/2026 |
| Dr. Kristin Yarema, PhD |
Interim Principal Financial Officer, Director and Chief Executive Officer |
美元 274.62K |
30/04/2026 |
|
|
| Mr. Joseph P. Slattery, C.P.A. |
Independent Director |
30/04/2026 |
| Dr. David P. Bonita, M.D. |
Lead Independent Director |
30/04/2026 |
| Dr. Jonathan Jian Wang, M.B.A.,PhD |
Chairman of the Board |
30/04/2026 |
| Dr. Weiguo Su, Pd.D |
Independent Director |
30/04/2026 |
| Dr. Kristin Yarema, PhD |
Interim Principal Financial Officer, Director and Chief Executive Officer |
30/04/2026 |
| Dr. Otello Stampacchia, PhD |
Independent Director |
30/04/2026 |
|
|
|
|
